Genfit (GNFT) EUR0.25

Sell:€10.00Buy:€10.16Price increased€0.59 (6.17%)

Market closed |
Prices delayed by at least 15 minutes
Sell:€10.00
Buy:€10.16
Change:Price increased€0.59 (6.17%)
Market closed |
Prices delayed by at least 15 minutes
Sell:€10.00
Buy:€10.16
Change:Price increased€0.59 (6.17%)
Market closed |
Prices delayed by at least 15 minutes

Company Information

About this company

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Key people

Jean-Francois Mouney
Chairman of the Board of Directors
Sakina Sayah-Jeanne
Chief Scientific Officer
Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Pejvack Motlagh
Chief Medical Officer
Sandra Silvestri
Director, Representative of IPSEN
Tristan Imbert
Independent Director
Katherine Bach Kalin
Independent Director
Pascal Prigent
Chief Executive Officer
Pascal Caisey
Deputy Chief Executive Officer, Chief Operating Officer
Eric Baclet
Independent Vice-Chairman of the Board of Directors
Thomas Baetz
Chief Financial Officer
Stefanie Magner
Executive Vice President - International Legal Affairs, Chief Compliance Officer
Emilie Desodt
Executive Vice President of Human Resources
John Brozek
Executive Vice President - Data and Information Technology, Director - Representative of Biotech Avenir SAS
Tom Huijbers
Executive Vice President - Regulatory
Click to see more

Key facts

  • Shares in issue
    50.04m
  • EPIC
    GNFT
  • ISIN
    FR0004163111
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    €479.42m
  • Employees
    188
  • Exchange
    Euronext Paris
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.